http://conairyoucurl.com/images/homepage/slider/slide-1.jpg
    • Leandro P. Rizzuto  Chairman in Perpetuity
    • Peter N. Foss  President, Advisory Board
    • Merit Cudkowicz MD Chief Medical Officer
    • Stanley H. Appel MD Advisory Board Member
    • Robert Brown D.Phil., MD Advisory Board Member
    • Tom Gentile  Advisory Board Member
    • Clive Svendsen PhD Advisory Board Member
    • Richard Ellenbogen MD Advisory Board Member
    • Randy Fishman  Advisory Board Member
    • Edward J. Rapp  Advisory Board Member
  • X

    Stanley H. Appel MD

    Advisory Board Member

    Stanley H. Appel, M.D. is the Director of the Houston Methodist Neurological Institute, Chair of the Department of Neurology, and the Edwards Distinguished Endowed Chair for ALS at Houston Methodist Hospital in Houston, TX. He is also Professor of Neurology at Weill Cornell Medical College.

    Dr. Appel is a native of Massachusetts and received his bachelor's degree at Harvard University and his medical degree from Columbia College of Physicians and Surgeons. He was previously Chair of the Department of Neurology at Baylor College of Medicine as well as Chief of the Neurology Division and the James B. Duke Professor of Medicine at Duke University Medical Center. Dr. Appel has served on a number of MDA advisory committees since 1991. He was named one of MDA's Honorary Vice Presidents from 1989 to 2003, and has been serving on MDA's national Board of Directors since 2003. He is Director of the MDA/ALS Research and Clinical Center at Houston Methodist Neurological Institute. Research in Dr. Appel's laboratory has focused on developing new insights into degenerative neurologic diseases, with primary emphasis on ALS. His studies of mutant SOD transgenic mice have documented that neuroinflammation and activated microglia are neuroprotective during early stages of disease and cytotoxic during late stages of disease. These two stages appear to be modulated by peripheral T-cells that enter the CNS at sites of neuronal injury; Th2 and regulatory T-cells are increased in early stages and appear to provide neuroprotection, while Th1 T-cells are increased in later stages and mediate cytotoxicity. Comparable studies in human ALS have employed PCR techniques to confirm the presence of activated microglia and to demonstrate the presence of CD4 T-cells as well as immature and mature dendritic cells and enhanced chemokine signaling.

    His laboratory was the first to document that regulatory T lymphocytes modulate disease progression in ALS patients. More specifically, regulatory T lymphocytes are decreased in ALS patients that progress at a faster rate; the levels of Treg may thus serve as a biomarker of rates of disease progression. His current efforts are focused on enhancing the protective immunity of Treg cells and anti-inflammatory microglia, and decreasing the proinflammatory immunity of Th1 effector lymphocytes and proinflammatory microglia.

    Dr. Appel is a member of numerous professional societies and committees, and is the author of 15 published books and over 400 articles on topics such as Amyotrophic Lateral Sclerosis (ALS), neuromuscular disease, Alzheimer's disease, and Parkinson's disease. He has received a number of awards for his accomplishments in neurology and biochemistry, including the 1997 Gold Medal for Excellence in Biomedical Research from Columbia College of Physicians and Surgeons, the 2003 Sheila Essey Award for ALS Research, 2004 MDA's Wings Over Wall Street Diamond Award, 2005 Texas Neurological Society Lifetime Achievement Award and the 2008 John P. McGovern Compleat Physician Award.

A Program Of

Advisory Board

  • Leandro P. Rizzuto
  • Peter N. Foss
  • Merit  Cudkowicz, MD
  • Denis  Rizzuto
  • Stanley H. Appel, MD
  • Robert  Brown, D.Phil., MD
  • Tom  Gentile
  • Clive  Svendsen, PhD
  • Richard  Ellenbogen, MD
  • Randy  Fishman
  • Edward J. Rapp